JavaScript seem to be disabled in your browser.
You must have JavaScript enabled in your browser to utilize the functionality of this website.
Briakinumab (ABT-874) is a human monoclonal antibody being developed by Abbott Laboratories for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. This the antibody targets the interleukins 12 and 23.